This section of our website is intended for healthcare professional
Do you work in healthcare?Abbonate (tranylcypromine)
Abbonate
Film-coated tablet 20 mg
For the treatment of severe depressive episodes in adults with treatment resistant major depressive disorder where adequate treatment with two standard antidepressants (including tricyclic antidepressants) and augmentation with, e.g. lithium, yielded an insufficient treatment response.*
The enzyme monoamine oxidase (MAO) plays an important role in the breakdown of neurotransmitters, such as serotonin, dopamine and noradrenaline. These substances play an important role in depression because a deficiency of these substances can cause mood disorders. By inhibiting the MAO enzyme, less breakdown occurs and this leads to an increase in the concentration of the neurotransmitters dopamine, serotonin and noradrenaline.
When treating with Abbonate, it is important that the patient follows a tyramine-restricted diet . In order to make it easier for the patient, we have produced a patient information sheet below for you to download.
Patient information can be downloaded here: Patient information
Patient card can be downloaded here: Patient card
Abbonate 20mg, 90 tablets
Vnr: 429504
Abbreviated product information
Abbonate 20 mg film-coated tablets, (tranylcypromine)
Psychoanaleptics. Antidepressants, MAO inhibitors, non-selective, ATC code: N06AF04. Rx, F.
Tyramine-rich foods and drinks should not be consumed from the start of treatment until 14 days after treatment with Abbonate. Patient information and patient cards are available via fass.se and abboxia.com. Indications: Treatment of major depressive episodes in adults with treatment-resistant major depression who have not responded to adequate standard treatment with at least two antidepressants (including tricyclic antidepressants) and augmentation with, for example, lithium. Contraindications: Hypersensitivity to tranylcypromine or any excipient, pheochromocytoma, carcinoid tumors, suspected or recent cerebrovascular event, vascular malformations, severe, poorly controlled forms of hypertension or cardiovascular disease, severe hepatic or renal impairment, porphyria, diabetes insipidus, malignant hyperthermia, acute delirium, acute intoxication with CNS depressants, psychotropic drugs and alcohol. Concomitant use of drugs that are strong serotonin reuptake inhibitors, tricyclic antidepressants, other MAO inhibitors, serotonin agonists, buspirone, sympathomimetics, pethidine, tramadol or dextromethorphan. Warnings and precautions: May aggravate existing symptoms such as anxiety and agitation, special caution in case of history of drug or alcohol abuse. May cause acute toxicity in overdose, consideration should be given to suicidal patients. May lower the threshold for seizures in patients with epilepsy. May affect blood sugar in patients with diabetes, insulin dose or dose of oral hypoglycemic drugs may need to be adjusted. Not recommended for women of childbearing potential who are not using contraception; a doctor should be contacted to change the medicine if the patient wishes to become pregnant or suspects pregnancy. Should not be used during breastfeeding. At the beginning of treatment, patients should not drive a car or other vehicles, use electrical tools and machines or perform other potentially dangerous tasks. Thereafter, the ability should be assessed individually for each patient. For further information and prices, see www.fass.se. Based on SmPC approved 2024-04-16. For questions or reporting of adverse events or complaints - contact regulatory@frostpharma.com.
